The therapeutic use of psychedelics is no longer a pipe dream – they are on the verge of potentially transforming the way we treat brain health disorders. As companies progress psychedelic therapies into phase three clinical studies for brain health disorders like anxiety, depression, PTSD, etc., the implications for healthcare are immense. Are patients, physicians, policymakers, and payers ready for it? This panel will explore the exciting future of psychedelic medicine, discussing how stakeholders can prepare for the regulatory, financial, and societal shifts that will come with it. Featuring insights from key opinion leaders including a leading pharmaceutical drug developer, a psychiatrist, professional organization representative, patient representative, and a healthcare payer. Panelists will explore critical questions such as: How do we ensure equitable access to these treatments? What are the challenges in scaling them for broad therapeutic use? And, how can we integrate them into existing healthcare systems?